SAN FRANCISCO -- Janus kinase (JAK) inhibitors appeared to be a safe, effective option for treating inflammatory bowel ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.In an interview with Healio, ...

Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...

Jason B. Pieper, DVM, MS, DACVD, talks about the multiple therapies available for cases of moderate and severe atopic dermatitis and delves into each option ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...